Study S000518

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00753896
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 134
Start: 2008-10
Primary completion: 2009-07
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:exenatide
Results posted: TRUE

Registered primary outcomes

Percentage of Patients Experiencing Adverse Events [Baseline to Week 52]
Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events [Baseline to Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018728	Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Norwood P, Clinical therapeutics	2012	Other trial	PMID 23031623 DOI	cites ClinicalTrials.gov:NCT00753896; registry reference DERIVED:23031623